So I've been digging through some of the smaller-cap plays trading under $10, and honestly there's been some interesting movement lately. The macro backdrop's pretty solid right now - rates are settling, 2026 earnings projections look solid, and that's got a lot of people looking to add positions in the sub-$10 space.

Most investors sleep on these dollar stocks that could explode, mainly because they're more volatile and less liquid than your typical blue chips. But if you actually know what to screen for, there's real opportunity here. The key is finding the ones with actual analyst support and improving fundamentals, not just random penny stocks getting pumped.

I've been looking at a specific screening approach - basically filtering for stocks under $10 with solid volume, strong analyst ratings, and most importantly, upward earnings revisions. That last part matters because it separates the real growth stories from the noise. You want at least a couple analysts covering the stock, and you want to see them raising their estimates, not cutting them.

One name that's caught my attention is Amicus Therapeutics (FOLD). It's a biotech play focused on rare diseases - Fabry disease, Pompe disease, that kind of niche but critical market. What's interesting is they just posted 17% revenue growth in Q3 and actually hit GAAP profitability, which is a big deal for a biotech company.

The numbers here are pretty compelling. They're projecting 19% revenue growth through 2026, targeting around $745 million in annual revenue. But the earnings expansion is where it gets spicy - they're looking at 50% earnings growth this year and 87% next year, with adjusted earnings potentially hitting $0.67 per share. That's a huge jump from where they were in 2024.

FOLD's been on a run too - up over 60% in the last six months and sitting right around $9.90. Analysts are seeing another 61% upside from here, and about 82% of the brokerage calls are Strong Buys. That's the kind of consensus you want to see on a dollar stock that could actually explode.

The thing is, there are roughly 70 stocks trading under $10 that fit this kind of quality screen right now. FOLD just happens to be one of the more interesting ones because it's got the growth trajectory, the analyst support, and the technical setup all lining up. If you're looking to find your next winner in the sub-$10 space, this is the kind of fundamental work that actually separates the signal from the noise.